CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
Aspirindrug
Likely dose
Aspirin 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04352439
NCT04352439Phase 4Completed
CompareCT.gov

Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy

Duke University·interventional·Posted Apr 20, 2020·Updated Sep 26, 2022

In Brief

A Phase 4 clinical trial evaluating Aspirin for Venous Thromboembolism and Ovarian Cancer. Completed, enrolled 19 participants across 2 sites.

Detailed Summary

This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism, Ovarian Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedApr 20, 2020
Enrollment StartAug 8, 2020
Primary CompletionMar 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.2 years ago

Interventions

Aspirindrug

81 mg aspirin daily